贝伐珠单抗、伊立替康、替莫唑胺、酪氨酸激酶抑制与MEK抑制对多形性黄色星形细胞瘤有效且与V600E状态无关
本研究在皮下和颅内多形性黄色星形细胞瘤(PXA)异种移植模型中筛选多种药物,发现替莫唑胺、贝伐珠单抗、伊立替康和索拉非尼在V600E突变型与非突变型皮下模型中均显著抑制肿瘤生长(P<0.05),MEK抑制剂cobimetinib同样有效而BRAF抑制剂vemurafenib无效;替莫唑胺、伊立替康和贝伐珠单抗在非突变型颅内模型中延长生存。
要点
- 替莫唑胺、贝伐珠单抗、伊立替康和索拉非尼在V600E突变型与非突变型PXA皮下模型中均显著抑制肿瘤生长。
- MEK抑制剂cobimetinib抑制肿瘤生长,而BRAF抑制剂vemurafenib无效,且与V600E状态无关。
- 替莫唑胺、伊立替康和贝伐珠单抗在V600E非突变型颅内模型中延长中位总生存期。
核心结论
- 作者认为,当PXA临床有辅助治疗指征时,可考虑替莫唑胺、伊立替康或贝伐珠单抗;无论V600E突变状态如何,可考虑试用MEK抑制剂或酪氨酸激酶抑制剂。
研究设计与样本
- 在两种皮下异种移植模型D645 PXA(V600E突变型)和D2363 PXA(V600E非突变型)中评估药物疗效,每组n=5-10只小鼠。
- 部分药物在D2363 PXA颅内模型中评估,n=6-9只小鼠。
- 评估药物包括贝伐珠单抗、替莫唑胺、洛莫司汀(CCNU)、伊立替康(CPT 11)、酪氨酸激酶抑制剂索拉非尼、选择性MEK1/2抑制剂cobimetinib和BRAF抑制剂vemurafenib。
- 终点为皮下肿瘤生长和生存。
主要发现
- 替莫唑胺、贝伐珠单抗、伊立替康和索拉非尼在V600E突变型和非突变型皮下模型中均显著抑制肿瘤生长(P<0.05)。
- MEK抑制剂cobimetinib抑制肿瘤生长(P<0.05),而BRAF抑制剂vemurafenib未抑制肿瘤生长,且与V600E突变状态无关。
- 在V600E非突变型颅内模型中,替莫唑胺、伊立替康和贝伐珠单抗延长生存,中位总生存期分别为68.5天、62.5天和42.5天,对照组为31.5天(P<0.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Pleomorphic xanthoastrocytoma (PXA) is a rare Grade II and III glioma. Surgical resection is the mainstay of treatment, however, adjuvant therapy is sometimes necessary. Given the rarity of PXA, chemotherapeutic efficacy data is limited. The importance of the BRAF V600E mutation in the context of MAP kinase pathway inhibition is unknown. The purpose of this study was to perform an in vivo screen of a variety to agents to determine efficacy against both V600E mutant and non-mutant PXA. METHODS: The efficacy of bevacizumab, temozolomide, lomustine (CCNU), irinotecan (CPT 11), a tyrosine kinase inhibitor (sorafenib), a selective MEK1/2 inhibitor (cobimetinib), and a BRAF inhibitor (vemurafenib) were assessed in two subcutaneous xenografts: D645 PXA (V600E-mutant) and D2363 PXA (V600E-non-mutant) (n = 5-10 mice). Select agents were also assessed in an intracranial model of D2363 PXA (n = 6-9). Subcutaneous tumor growth and survival were the endpoints. RESULTS: Temozolomide, bevacizumab, CPT 11, and sorafenib significantly inhibited subcutaneous tumor growth in both V600E-mutant and V600E-non-mutant models (P < 0.05). MEK inhibition (cobimetinib) but not BRAF inhibition (vemurafenib) also inhibited tumor growth regardless of V600E mutation (P < 0.05). Temozolomide, CPT 11, and bevacizumab also prolonged survival in a V600E-non-mutant intracranial model (median overall survival (OS) 68.5, 62.5, and 42.5 days, respectively) in contrast to controls (31.5 days, P < 0.001). CONCLUSIONS: These findings suggest that when adjuvant treatment is clinically indicated for PXA, temozolomide, CPT 11, or bevacizumab may be considered. Additionally, a trial of a MEK inhibitor or tyrosine kinase inhibitor could be considered for PXA regardless of V600E mutation status.
引用
- Thompson EM, Landi D, Ashley D, et al. Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status. J Neurooncol. 2018. PMID: 30120661. doi:10.1007/s11060-018-2975-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。